Arne Kristian Skulberg

  • Senior Physician, Researcher; MD, PhD

I have been working on opioid overdoses, and the development of a naloxone nasal spray together with Prof. Ola Dale and NTNU for the last decade. This has involved pharmacokinetic studies in heathy volunteers and a larger randomized trial comparing intranasal and intramuscular naloxone administered by Ambulance works in Oslo and Trondheim. 

I work as a consultant anesthetist at Legebilen 119, a physician manned ambulance in the Oslo Metropolitan area. 

Arne Skulberg (researchgate.net)

 

Publications 2025

Utrilla MG, Chesney E, Neale J, Metrebian N, Kalk N, Skulberg AK, Dietze P, Smith M, Strang J (2025)
Naloxone dosing in the era of synthetic opioids: Applying the Goldilocks principle
Addiction (in press)
DOI 10.1111/add.70060, PubMed 40197810

Publications 2024

Eide D, Gjersing L, Danielsen AW, Skulberg AK, Dale O, Braarud AC, Heyerdahl F, Tylleskar I (2024)
Heightened mortality risk after a non-fatal opioid overdose: Risk factors for mortality in the week following emergency treatment
Addiction, 119 (12), 2131-2138
DOI 10.1111/add.16632, PubMed 39183709

Skulberg AK, Heyerdahl F, Dale O, Eide D (2024)
[Not Available]
Tidsskr Nor Laegeforen, 144 (8)
DOI 10.4045/tidsskr.24.0202, PubMed 38934313

Publications 2022

Hagemo JS, Skulberg AK, Rehn M, Valberg M, Pesonen M, Heimdal HJ, Heyerdahl F (2022)
Inhaled nitric oxide as temporary respiratory stabilization in patients with COVID-19 related respiratory failure (INOCOV): Study protocol for a randomized controlled trial
PLoS One, 17 (5), e0268822
DOI 10.1371/journal.pone.0268822, PubMed 35622848

Skulberg AK, Tylleskär I, Dale O (2022)
Naloxone administration-no balance without titration
Addiction, 117 (10), 2750-2751
DOI 10.1111/add.15947, PubMed 35589622

Skulberg AK, Tylleskär I, Valberg M, Braarud AC, Dale J, Heyerdahl F, Skålhegg T, Barstein J, Mellesmo S, Dale O (2022)
Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy, randomised, controlled trial
Addiction, 117 (6), 1658-1667
DOI 10.1111/add.15806, PubMed 35137493

Publications 2021

Brede JR, Skulberg AK, Rehn M, Thorsen K, Klepstad P, Tylleskär I, Farbu B, Dale J, Nordseth T, Wiseth R, Krüger AJ (2021)
REBOARREST, resuscitative endovascular balloon occlusion of the aorta in non-traumatic out-of-hospital cardiac arrest: a study protocol for a randomised, parallel group, clinical multicentre trial
Trials, 22 (1), 511
DOI 10.1186/s13063-021-05477-1, PubMed 34332617

Skulberg AK, Tylleskar I, Dale O (2021)
Intranasal Naloxone Administration
N Engl J Med, 384 (24), e96
DOI 10.1056/NEJMc2106983, PubMed 34133872

Skulberg AK, Tylleskar I, Dale O, Ortega R, Nozari A, Baker W (2021)
Intranasal Naloxone Administration REPLY
N. Engl. J. Med., 384 (24)

Tylleskar I, Skarra S, Skulberg AK, Dale O (2021)
The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers
Eur J Clin Pharmacol, 77 (12), 1901-1908
DOI 10.1007/s00228-021-03190-1, PubMed 34327552

Publications 2020

Skulberg AK, Tylleskär I, Braarud AC, Dale J, Heyerdahl F, Mellesmo S, Valberg M, Dale O (2020)
NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use
BMJ Open, 10 (11), e041556
DOI 10.1136/bmjopen-2020-041556, PubMed 33184084

Tylleskar I, Gjersing L, Bjørnsen LP, Braarud AC, Heyerdahl F, Dale O, Skulberg AK (2020)
Prehospital naloxone administration - what influences choice of dose and route of administration?
BMC Emerg Med, 20 (1), 71
DOI 10.1186/s12873-020-00366-3, PubMed 32891142

Publications 2019

Skulberg AK, Åsberg A, Khiabani HZ, Røstad H, Tylleskar I, Dale O (2019)
Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial
Addiction, 114 (5), 859-867
DOI 10.1111/add.14552, PubMed 30644628

Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Dale O (2019)
Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study
Tidsskr Nor Laegeforen, 139 (13)
DOI 10.4045/tidsskr.19.0162, PubMed 31556537

Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Dale O (2019)
Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study
Tidsskr. Nor. Laegeforen., 139 (13), 1260-1264

Publications 2018

Madah-Amiri D, Skulberg AK, Braarud AC, Dale O, Heyerdahl F, Lobmaier P, Clausen T (2018)
Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facility
Subst Abus, 40 (3), 383-388
DOI 10.1080/08897077.2018.1485130, PubMed 29949448

Skulberg AK, Tylleskar I, Nilsen T, Skarra S, Salvesen Ø, Sand T, Loftsson T, Dale O (2018)
Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers
Eur J Clin Pharmacol, 74 (7), 873-883
DOI 10.1007/s00228-018-2443-3, PubMed 29568976

Tylleskar I, Skulberg AK, Skarra S, Nilsen T, Dale O (2018)
Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil
Eur J Clin Pharmacol, 74 (12), 1547-1553
DOI 10.1007/s00228-018-2545-y, PubMed 30143830

Publications 2017

Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Jansook P, Dale O (2017)
Pharmacokinetics of a new, nasal formulation of naloxone
Eur J Clin Pharmacol, 73 (5), 555-562
DOI 10.1007/s00228-016-2191-1, PubMed 28144724

Publications 2016

Skulberg AK, Mathisen LC, Vaagbø G (2016)
[Treatment of air embolisms]
Tidsskr Nor Laegeforen, 136 (12-13), 1070
DOI 10.4045/tidsskr.16.0455, PubMed 27381784

Scroll to top